Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26232021 | 0.94 | KMT2A (0.50) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL29799591 | 0.94 | KMT2A (0.50) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL31648532 | 0.94 | KMT2A (0.50) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL31287180 | 0.94 | KMT2A (0.50) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL29661423 | 0.91 | KMT2A (0.58) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL24401717 | 0.90 | KMT2A (0.55) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL2242449 | 0.90 | KMT2A (0.55) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL26689241 | 0.89 | KMT2A (0.53) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL26689394 | 0.89 | KMT2A (0.53) | KMT2APTPN1TLR2CASP3 | |
| SCHEMBL26689238 | 0.89 | KMT2A (0.53) | KMT2APTPN1TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016196124-A2 | PRODRUGS COMPRISING A PYROGLUTAMATE LINKER | ASCENDIS PHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | KMT2A 2364/4885PTPN1 4403/4885TLR2 3900/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | KMT2A 2364/4885PTPN1 4403/4885TLR2 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.